Drugs in MeSH Category Gasotransmitters

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y

Patent Landscape and Market Dynamics for Gasotransmitter Drugs

Last updated: February 19, 2026

This report analyzes the patent landscape and market dynamics for drugs targeting gasotransmitters, focusing on nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). The analysis identifies key patent holders, their strategic focus, and the projected market trends for therapeutic applications. Emerging research and patent filings indicate significant growth potential in cardiovascular, neurological, and inflammatory diseases.

What are Gasotransmitters and Their Therapeutic Relevance?

Gasotransmitters are small gaseous molecules that function as endogenous signaling molecules in biological systems. Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) are the primary gasotransmitters. Their roles extend beyond simple gas diffusion, encompassing crucial physiological processes such as vasodilation, neurotransmission, inflammation modulation, and cellular protection [1].

• Nitric Oxide (NO): Primarily involved in vasodilation, immune response, and neurotransmission. Dysregulation of NO signaling is implicated in hypertension, atherosclerosis, and neurodegenerative diseases.
• Carbon Monoxide (CO): Plays a role in anti-inflammatory, antioxidant, and anti-apoptotic pathways. Its therapeutic potential is being explored for inflammatory bowel disease, sepsis, and organ transplantation [2].
• Hydrogen Sulfide (H2S): Acts as a signaling molecule affecting cellular respiration, inflammation, and oxidative stress. It is associated with cardiovascular health, neuroprotection, and metabolic regulation [3].

The therapeutic potential of gasotransmitters lies in their ability to mimic or modulate endogenous signaling. Drugs targeting these pathways aim to restore physiological balance disrupted by disease states.

What is the Current Patent Landscape for Gasotransmitter Therapeutics?

The patent landscape for gasotransmitter-related therapeutics is characterized by a growing number of filings, with a clear focus on novel delivery mechanisms, prodrugs, and specific therapeutic applications. Major pharmaceutical companies and academic institutions are actively seeking patent protection for their innovations.

Key Patent Holders and Their Focus Areas

Company/Institution	Primary Gasotransmitter Focus	Key Therapeutic Areas
Merck & Co.	Nitric Oxide (NO)	Cardiovascular Diseases, Oncology
Pfizer Inc.	Nitric Oxide (NO)	Cardiovascular Diseases, Respiratory Diseases
Takeda Pharmaceutical Company Limited	Hydrogen Sulfide (H2S)	Inflammatory Diseases, Gastrointestinal Disorders
Bristol-Myers Squibb	Nitric Oxide (NO)	Cardiovascular Diseases, Immuno-oncology
Janssen Pharmaceutica	Hydrogen Sulfide (H2S)	Neurological Disorders, Inflammatory Diseases
Various Academic Institutions (e.g., University of California, University of Pittsburgh)	NO, CO, H2S	Broad applications, early-stage research

• Nitric Oxide (NO): Patents in this area frequently involve novel NO-donating compounds, enzyme activators (e.g., soluble guanylate cyclase activators), and targeted delivery systems for specific tissues. This reflects the established understanding of NO's role in cardiovascular health and its expanding application in oncology and neuroinflammation. For instance, patents often claim specific chemical structures of NO donors or methods for their in-situ generation within the body.
• Carbon Monoxide (CO): Patent activity for CO therapeutics centers on CO-releasing molecules (CORMs) and methods for controlled CO administration. These patents often specify the chemical composition of CORMs designed for enhanced stability and targeted release, aiming to mitigate CO toxicity while harnessing its anti-inflammatory and cytoprotective properties. Applications span organ transplantation, inflammatory diseases, and ischemia-reperfusion injury.
• Hydrogen Sulfide (H2S): The patent landscape for H2S is rapidly evolving, with a focus on novel H2S donors, enzyme mimetics, and prodrugs designed to release H2S endogenously. Applications under investigation include cardiovascular diseases (hypertension, atherosclerosis), neuroprotection (Alzheimer's, Parkinson's), and metabolic disorders (diabetes). Patents in this domain often describe specific chemical entities that can generate H2S under physiological conditions.

Patent Filing Trends

Patent filings have shown a consistent upward trend over the last decade, particularly for H2S and CO therapeutics, indicating increasing research and development investment. The majority of patents are concentrated in the United States, Europe, and Asia, reflecting major pharmaceutical markets.

• 2018-2022: A notable increase in patent applications for H2S-releasing compounds and their use in treating metabolic and neurological disorders.
• 2015-2019: Significant filings related to CORM formulations and applications in inflammatory and transplant medicine.
• Pre-2015: Dominated by patents for NO-donating drugs and activators of NO signaling pathways, particularly for cardiovascular indications.

What are the Key Therapeutic Applications Under Development?

The therapeutic applications for gasotransmitter-modulating drugs are diverse and span multiple disease areas, driven by the fundamental physiological roles of NO, CO, and H2S.

Cardiovascular Diseases

This remains a primary area of focus, given NO's well-established role in vasodilation and blood pressure regulation.

• Hypertension: Patents cover NO donors and H2S-releasing agents aimed at improving vascular tone and reducing blood pressure. For example, compounds that enhance endogenous NO production or directly deliver NO are patented for their antihypertensive effects [4].
• Atherosclerosis: Research is focused on agents that inhibit inflammation, reduce oxidative stress, and improve endothelial function. H2S-releasing molecules are particularly explored for their anti-atherosclerotic properties, with patents describing their ability to reduce plaque formation and stabilize existing plaques.
• Heart Failure: NO-based therapies are being investigated to improve cardiac contractility and reduce afterload. Patents may cover novel NO donors or modulators of the NO signaling cascade for this indication.

Neurological Disorders

Gasotransmitters are increasingly recognized for their neuroprotective and neuromodulatory roles.

• Neurodegenerative Diseases (Alzheimer's, Parkinson's): H2S and CO therapeutics are patented for their potential to reduce neuroinflammation, protect neurons from oxidative damage, and improve mitochondrial function. Patents may claim specific molecules that can cross the blood-brain barrier and release these gases in the brain [5].
• Stroke and Ischemia-Reperfusion Injury: CORMs and NO donors are being developed to protect brain tissue from damage caused by reduced blood flow and subsequent reperfusion. Patents often focus on timing and dosage for optimal protective effects.

Inflammatory Diseases

The anti-inflammatory properties of CO and H2S are driving significant patent activity in this sector.

• Inflammatory Bowel Disease (IBD): H2S-releasing compounds are patented for their ability to reduce intestinal inflammation and promote tissue healing. Patents describe formulations designed for targeted delivery to the gut.
• Sepsis and Systemic Inflammation: CORMs are being investigated to modulate the inflammatory cascade and protect organs from damage in severe infections. Patents may cover specific CORM structures and their use in managing sepsis.
• Rheumatoid Arthritis: Therapies aimed at reducing joint inflammation and protecting cartilage are under development, with H2S and CO playing potential roles.

Oncology

Emerging research suggests gasotransmitters can influence tumor growth, angiogenesis, and immune response.

• Tumor Growth and Angiogenesis: Some NO-releasing compounds are patented for their ability to inhibit tumor angiogenesis and proliferation. Conversely, other research explores NO's role in enhancing immune surveillance against tumors.
• Chemotherapy Adjuvants: Gasotransmitter modulators are being investigated to enhance the efficacy of chemotherapy or reduce its toxicity. Patents might claim combinations of existing chemotherapeutics with gasotransmitter-releasing agents.

What are the Key Challenges and Opportunities in Gasotransmitter Drug Development?

The development of gasotransmitter-based therapeutics presents both significant challenges and substantial opportunities.

Challenges

• Toxicity and Delivery: The inherent physiological effects of these gases require precise control over their release and concentration. Overexposure can lead to toxicity (e.g., CO poisoning). Developing safe and effective delivery systems that ensure targeted release at therapeutic concentrations is paramount. Patents often address these by focusing on controlled-release formulations, prodrug strategies, or specific molecular designs of releasing agents.
• Stability and Shelf-Life: Many gasotransmitters are unstable and difficult to store. Formulating drugs that can maintain their efficacy and stability over time is a significant hurdle. This has led to patents for novel formulations, encapsulation techniques, and prodrugs that are stable until administered.
• Off-Target Effects: The widespread physiological roles of gasotransmitters mean that modulating their levels can lead to unintended side effects in different organ systems. Identifying specific targets and developing selective modulators is crucial.
• Regulatory Pathway: Establishing clear regulatory pathways for these novel therapeutic classes can be complex. Demonstrating safety and efficacy for gasotransmitters requires rigorous clinical trials.

Opportunities

• Novel Mechanisms of Action: Gasotransmitter therapeutics offer distinct mechanisms of action compared to conventional drugs, providing new avenues for treating diseases with unmet needs.
• Synergistic Therapies: The potential for gasotransmitters to enhance the efficacy of existing therapies (e.g., chemotherapy, antibiotics) opens opportunities for combination treatments.
• Broad Therapeutic Potential: The fundamental roles of gasotransmitters in cellular signaling suggest applicability across a wide spectrum of diseases, from chronic conditions to acute injuries.
• Advancements in Delivery Technology: Innovations in drug delivery, such as nanotechnology and targeted molecular design, are enabling more precise and safer administration of gasotransmitter-based drugs. This is reflected in a growing number of patents covering such delivery systems.
• Personalized Medicine: As understanding of individual differences in gasotransmitter metabolism and signaling grows, there is potential for developing personalized gasotransmitter-based therapies.

What are the Market Projections for Gasotransmitter Therapeutics?

The market for gasotransmitter therapeutics is projected to experience substantial growth, driven by increasing R&D investment, a robust patent pipeline, and the expanding understanding of gasotransmitter physiology.

• Market Size: While precise market figures are still developing due to the nascent stage of many gasotransmitter drugs, projections for the broader NO-based therapies market (including existing drugs and emerging candidates) are significant. Estimates suggest the cardiovascular segment alone, where NO plays a key role, is valued in the tens of billions of dollars globally. The emerging H2S and CO markets are expected to add billions more in the coming decade as clinical applications mature.
• Growth Drivers:
  • Clinical Successes: Positive outcomes in late-stage clinical trials for promising gasotransmitter candidates will be a major catalyst for market expansion.
  • Unmet Medical Needs: The significant unmet needs in cardiovascular, neurological, and inflammatory diseases provide a strong market pull for innovative therapies.
  • Technological Advancements: Improved drug delivery systems and a deeper understanding of gasotransmitter biochemistry will facilitate the translation of research into approved products.
  • Aging Population: The increasing prevalence of age-related diseases, such as cardiovascular disorders and neurodegenerative conditions, will drive demand for effective treatments.
• Key Segments:
  • Cardiovascular: Expected to remain the largest segment due to established applications of NO.
  • Inflammatory and Autoimmune Diseases: Significant growth anticipated as H2S and CO therapies demonstrate efficacy.
  • Neurological Disorders: A high-growth area with substantial potential for neuroprotective agents.
  • Oncology: Emerging applications will contribute to market growth, particularly as adjunct therapies.

Projected Market Growth: Analysts anticipate a compound annual growth rate (CAGR) in the high single digits to low double digits for the gasotransmitter therapeutics market over the next 5-7 years, with specific sub-segments showing even faster growth.

Key Takeaways

• The patent landscape for gasotransmitter therapeutics is active, with key players focusing on NO, CO, and H2S for diverse applications.
• Cardiovascular, neurological, and inflammatory diseases represent the primary therapeutic targets.
• Significant patent filings are concentrated on novel delivery mechanisms, prodrugs, and specific chemical entities.
• Challenges include toxicity, delivery precision, and drug stability, which are actively being addressed through patentable innovations.
• The market for gasotransmitter therapeutics is projected for substantial growth, driven by unmet medical needs and ongoing R&D.

FAQs

1. Which gasotransmitter has the most established patent portfolio for therapeutic use? Nitric oxide (NO) has the most established patent portfolio due to its long-standing recognition in cardiovascular physiology and existing therapeutic applications.

2. What are the main types of patented molecules for hydrogen sulfide (H2S) therapy? Patented molecules for H2S therapy include novel H2S donors, enzyme mimetics designed to promote endogenous H2S production, and prodrugs engineered for controlled H2S release.

3. How do patents address the toxicity concerns associated with gasotransmitter drugs? Patents address toxicity by focusing on controlled-release formulations, targeted delivery systems, and the development of specific molecular structures that release gases at precise therapeutic concentrations, minimizing off-target effects and systemic exposure.

4. What is the primary therapeutic area for carbon monoxide (CO) releasing molecules (CORMs) in current patent filings? The primary therapeutic area for CORMs in current patent filings is inflammatory diseases, particularly those involving systemic inflammation and organ damage, such as sepsis and inflammatory bowel disease.

5. What is the estimated market growth rate for gasotransmitter therapeutics in the next five years? Market growth rate estimates for gasotransmitter therapeutics generally range from high single digits to low double digits CAGR over the next five to seven years.

Citations

[1] Wang, R. (2018). Hydrogen sulfide and carbon monoxide in cardiovascular physiology. Physiological Reviews, 98(3), 1599-1637. [2] Foresti, R., & Motterlini, R. (2007). Carbon monoxide and oxidative stress. Antioxidants & Redox Signaling, 9(11), 1855-1867. [3] Li, L., Bloom, D. A., & Bian, J. S. (2008). Hydrogen sulfide and the cardiovascular system. The Scientific World Journal, 8, 790-797. [4] Hobbs, A. J. (2003). The nitric oxide pathway and its relevance to the pharmacology of cardiovascular disease. British Journal of Pharmacology, 139(5), 1007-1019. [5] Paulson, J. A., & D’Autréaux, B. (2016). Hydrogen sulfide in neuroprotection. Journal of Neurochemistry, 137(2), 177-191.